[go: up one dir, main page]

IN2015DN02349A - - Google Patents

Download PDF

Info

Publication number
IN2015DN02349A
IN2015DN02349A IN2349DEN2015A IN2015DN02349A IN 2015DN02349 A IN2015DN02349 A IN 2015DN02349A IN 2349DEN2015 A IN2349DEN2015 A IN 2349DEN2015A IN 2015DN02349 A IN2015DN02349 A IN 2015DN02349A
Authority
IN
India
Prior art keywords
conjugates
specific
peptide
binding protein
drug
Prior art date
Application number
Other languages
English (en)
Inventor
Limited Polytherics
Original Assignee
Polytherics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2013/051593 external-priority patent/WO2013190292A2/en
Application filed by Polytherics Ltd filed Critical Polytherics Ltd
Publication of IN2015DN02349A publication Critical patent/IN2015DN02349A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
IN2349DEN2015 2012-10-24 2013-10-11 IN2015DN02349A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261717743P 2012-10-24 2012-10-24
US201261717710P 2012-10-24 2012-10-24
US201361811285P 2013-04-12 2013-04-12
PCT/GB2013/051593 WO2013190292A2 (en) 2012-06-19 2013-06-19 Novel process for preparation of antibody conjugates and novel antibody conjugates
PCT/GB2013/052661 WO2014064423A1 (en) 2012-10-24 2013-10-11 Drug-protein conjugates

Publications (1)

Publication Number Publication Date
IN2015DN02349A true IN2015DN02349A (pt) 2015-08-28

Family

ID=50544085

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2349DEN2015 IN2015DN02349A (pt) 2012-10-24 2013-10-11

Country Status (18)

Country Link
US (2) US20150290342A1 (pt)
EP (2) EP3159013A1 (pt)
JP (1) JP6328648B2 (pt)
KR (1) KR102209395B1 (pt)
CN (1) CN104870021B (pt)
AU (1) AU2013336409B2 (pt)
BR (1) BR112015008376A2 (pt)
CA (1) CA2884299A1 (pt)
DK (1) DK2911700T5 (pt)
ES (1) ES2623209T3 (pt)
IL (1) IL237672B (pt)
IN (1) IN2015DN02349A (pt)
MX (1) MX2015005122A (pt)
MY (1) MY169147A (pt)
RU (1) RU2015119561A (pt)
SG (1) SG11201501618WA (pt)
WO (1) WO2014064423A1 (pt)
ZA (1) ZA201501642B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3003387A1 (en) 2013-06-04 2016-04-13 Cytomx Therapeutics Inc. Compositions and methods for conjugating activatable antibodies
AU2014337555C1 (en) 2013-10-15 2021-01-28 Seagen Inc. PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics
WO2015179734A1 (en) * 2014-05-23 2015-11-26 Novartis Ag Methods for making conjugates from disulfide-containing proteins
KR102451080B1 (ko) * 2014-06-12 2022-10-06 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. 효소적 방법을 통한 균일한 항체 약물 접합체
ES2885854T3 (es) * 2014-10-14 2021-12-15 Polytherics Ltd Proceso para la conjugación de un péptido o proteína con un reactivo que comprende un grupo saliente que incluye una porción de PEG
KR102513926B1 (ko) * 2014-10-24 2023-03-23 폴리테릭스 리미티드 접합체 및 접합 시약
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
EP3165532B1 (en) 2015-11-03 2018-12-19 Industrial Technology Research Institute Auristatin derivatives, linker-drugs and ligand-drug conjugates
TWI852735B (zh) 2015-12-04 2024-08-11 美商思進公司 四級胺化妥布賴森(tubulysin)化合物之結合物
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
EP3433278A4 (en) 2016-03-25 2019-11-06 Seattle Genetics, Inc. METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF
WO2017178828A1 (en) * 2016-04-14 2017-10-19 Polytherics Limited Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring
GB201608936D0 (en) 2016-05-20 2016-07-06 Polytherics Ltd Novel conjugates and novel conjugating reagents
ES2965349T3 (es) * 2016-06-06 2024-04-12 Abzena Uk Ltd Anticuerpos, usos de los mismos y conjugados de los mismos
GB201614162D0 (en) * 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
SG11201908325PA (en) 2017-03-24 2019-10-30 Seattle Genetics Inc Process for the preparation of glucuronide drug-linkers and intermediates thereof
GB201820864D0 (en) * 2018-12-20 2019-02-06 J A Kemp Antibody-drug conjugates
WO2021209007A1 (en) * 2020-04-15 2021-10-21 Shenzhen Enduring Biotech, Ltd. Antibody-drug conjugate
US20240181074A1 (en) * 2021-03-19 2024-06-06 Shenzhen Enduring Biotech, Ltd. Pegylated t cell engager with dual specificities to cd3 and cd19
WO2023141855A1 (en) * 2022-01-27 2023-08-03 Glyco-Therapy Biotechnology Co., Ltd. Protein conjugates with multiple payloads and methods for making the same
TW202444426A (zh) * 2023-03-29 2024-11-16 美商艾克塞里克斯公司 Amhrii抗體-藥物結合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
PT1725249E (pt) 2003-11-06 2014-04-10 Seattle Genetics Inc Compostos de monometilvalina capazes de conjugação a ligandos
BRPI0617546A2 (pt) * 2005-09-26 2011-07-26 Medarex Inc conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
PL2265283T3 (pl) 2008-03-18 2015-03-31 Seattle Genetics Inc Koniugaty aurystatyny lek łącznik
AU2009243009B2 (en) * 2008-04-30 2014-09-11 Immunogen, Inc Potent conjugates and hydrophilic linkers
US9005598B2 (en) 2009-03-04 2015-04-14 Polytherics Limited Conjugated proteins and peptides
SG174992A1 (en) * 2009-04-01 2011-11-28 Genentech Inc Anti-fcrh5 antibodies and immunoconjugates and methods of use
TW201117814A (en) * 2009-10-02 2011-06-01 Sanofi Aventis New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
JP6384963B2 (ja) * 2012-04-25 2018-09-05 コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. 勾配コイルを置くためのシステム及び方法
IN2014DN10428A (pt) * 2012-06-19 2015-08-21 Polytherics Ltd

Also Published As

Publication number Publication date
KR20150103656A (ko) 2015-09-11
US20150290342A1 (en) 2015-10-15
IL237672A0 (en) 2015-04-30
HK1208187A1 (en) 2016-02-26
MX2015005122A (es) 2015-10-29
ZA201501642B (en) 2016-01-27
RU2015119561A (ru) 2016-12-20
SG11201501618WA (en) 2015-04-29
CN104870021B (zh) 2018-03-13
EP3159013A1 (en) 2017-04-26
DK2911700T5 (en) 2017-05-22
JP6328648B2 (ja) 2018-05-23
ES2623209T3 (es) 2017-07-10
EP2911700A1 (en) 2015-09-02
CN104870021A (zh) 2015-08-26
US20220062436A1 (en) 2022-03-03
JP2015533847A (ja) 2015-11-26
KR102209395B1 (ko) 2021-01-28
AU2013336409A1 (en) 2015-04-02
DK2911700T3 (en) 2017-05-15
IL237672B (en) 2018-02-28
AU2013336409B2 (en) 2017-08-03
WO2014064423A1 (en) 2014-05-01
EP2911700B1 (en) 2017-02-08
BR112015008376A2 (pt) 2017-09-26
CA2884299A1 (en) 2014-05-01
MY169147A (en) 2019-02-18

Similar Documents

Publication Publication Date Title
IN2015DN02349A (pt)
CY1122490T1 (el) Αντισωματα κατα του ανθρωπινου cd38
MX2015005124A (es) Conjugados de farmaco-proteina.
MY168297A (en) Cytotoxic Peptides and Antibody Drug Conjugates Thereof
TN2013000245A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib
PH12015500390A1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
EA201691023A1 (ru) Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
NZ703581A (en) Anti-cd70 antibody drug conjugates
NZ730763A (en) Methods of treating a tauopathy
TN2015000396A1 (en) Antibody drug conjugates
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
UA113712C2 (xx) Антитіло до fap і способи його застосування
MY164577A (en) Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
MX340062B (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y ciclofosfamida.
PH12018500159A1 (en) Constructs targeting psa peptide/mhc complexes and uses thereof
PH12013500432A1 (en) Anti-vegfr-3 antibody compositions
MX2013003168A (es) Anticuerpo contra ephrin b2 y su uso.
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions
TN2011000153A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide